Leadership is ultimately measured by results, not press releases. And in Maryland, the numbers behind Governor Wes Moore’s highly publicized AstraZeneca deal tell a very different story than the victory lap he’s taking in the headlines. While the Governor celebrates what he calls a “transformational investment” in Maryland’s life sciences sector, the fine print reveals a deal that is astonishingly expensive for taxpayers, remarkably light on real job growth, and emblematic of an administration that cannot negotiate from a position of strength.
Let’s start with the basics. AstraZeneca is investing $2 billion to expand its manufacturing capacity in Frederick and build a new clinical facility in Gaithersburg. On its face, private investment in Maryland is a good thing. Republicans support growth, innovation, and a strong business climate. But where the Moore administration falls flat is the cost it’s forcing Maryland taxpayers to shoulder for relatively little guaranteed return.
The state, along with local jurisdictions, is providing an estimated 10% public match on the total project cost. For Maryland alone, that includes $116.5 million in capital budget commitments over eight years, with additional public contributions expected locally. For that price tag, Maryland promises roughly 300 new permanent jobs, 200 in Frederick and 100 in Gaithersburg, along with the retention of 400 existing roles.
Do the math: taxpayers are effectively paying $600,000–$700,000 per permanent job.
And that’s the best-case interpretation.
The Moore administration inflates the job count by touting “2,600 jobs supported,” a figure that conveniently lumps in temporary construction positions and “supported” jobs that cannot be meaningfully verified or guaranteed. Marylanders cannot retire or send their kids to college on a temporary construction gig. What matters are long-term, high-quality jobs, and Moore delivers just 300 new ones, at a breathtaking cost.
This is not economic development. It’s economic naïveté.
What’s even more troubling is what the announcement didn’t include. No wage guarantees. No local-hire mandates. No claw-back protections for taxpayers if AstraZeneca automates jobs, shrinks operations, or relocates in five or ten years. And no transparency about who will actually fill these new roles. Will they be Marylanders? Or will AstraZeneca transfer employees from out of state while the Moore administration counts them as “new jobs”?
A serious governor would have demanded safeguards.
A skilled negotiator would have insisted on performance thresholds.
A leader with private-sector experience would have recognized that corporations respond not to fanfare, but to firm expectations, enforceable commitments, and strategic incentives.
But Maryland doesn’t have that leader.
What we have instead is a governor who measures success by the size of the ribbon-cutting ceremony, not the fiscal responsibility behind it.
The contrast with Republican-led states is stark. In Florida, Texas, Virginia, and Georgia, governors routinely negotiate deals with performance-based incentives you get the tax credit only after creating the jobs. In North Carolina, large corporate deals include refund clauses if targets aren’t met. In Tennessee, all major subsidies require clear wage floors to prevent companies from padding job numbers with low-wage positions.
Maryland, under Moore, gets none of that. We get big promises, big taxpayer checks, and vague projections wrapped in polished talking points.
To be clear: biotech investment is a positive force. Maryland should absolutely be a national leader in life sciences. Companies like AstraZeneca are essential to our economy. But public sector leaders must negotiate from strength, with discipline and with accountability. Instead, Marylanders are being told to applaud a deal that gives away millions in taxpayer money while delivering only a few hundred new permanent jobs and no meaningful protections.
This is not how a competitive state behaves.
Maryland’s problem isn’t that we’re investing in biotech. The problem is how poorly we are negotiating these deals. Moore is treating economic development like a charity operation, one that writes extensive checks with public money and simply “hopes” the private-sector return will make it worthwhile someday.
That’s not leadership. That’s wishful thinking.
Maryland deserves a governor who understands leverage, demands accountability, and negotiates deals that create widespread opportunities, not just headlines. Until then, taxpayers will keep footing oversized bills for undersized results.
And that is the real cost of the Moore administration.
Endnotes
- Baltimore Sun. “AstraZeneca to invest $2 billion as part of U.S. manufacturing push.” November 21, 2025.
https://www.baltimoresun.com/2025/11/21/wes-moore-astrazeneca-2-billion-investment-jobs/ - Office of Governor Wes Moore. “Governor Moore and AstraZeneca Announce $2 Billion Investment to Expand Manufacturing in Maryland, Supporting 2,600 Jobs.” Maryland.gov Press Release, November 2025.
https://governor.maryland.gov/news/press/pages/Governor-Moore-and-AstraZeneca-Announce-$2-Billion-Investment-to-Expand-Manufacturing-in-Maryland,-Supporting-2,600-Jobs.aspx - Ibid. Breakdown of job numbers: 200 new jobs in Frederick, 900 construction roles, 100 new jobs in Gaithersburg, 400 retained roles, and an estimated 1,000 construction-supported jobs.
- Ibid. Public funding details: Maryland’s “approximately 10% investment match,” including $116.5 million in capital budget commitments over eight years.
- Reuters. “AstraZeneca to invest $2 billion as part of U.S. manufacturing push.” November 21, 2025.
- Fierce Pharma. “AstraZeneca boosts its presence in Maryland with $2B manufacturing investment.” November 2025.
- WBAL-TV 11. “AstraZeneca’s $2B investment in Maryland will expand Frederick and Gaithersburg manufacturing.” November 2025.
- BioPharma International. “What a $2 Billion Maryland Expansion Means for the Future of Biologics Production.” November 2025.
- Comparison with Republican-led states based on publicly available state incentive frameworks:
• Texas Enterprise Fund (TEF) performance-based grants
• Florida Qualified Target Industry (QTI) tax refund program
• Virginia Commonwealth Opportunity Fund (COF) wage- and job-verified grants
• Tennessee Department of Economic & Community Development performance contracts (2023–2025 summaries) - National Bureau of Economic Research (NBER): Literature on “cost per job” for state corporate incentives, including estimates showing diminishing taxpayer returns when subsidies exceed $150,000 per permanent job.
- Government Accountability Office (GAO). Report on state economic development subsidies and the need for accountability mechanisms such as claw-backs and job-creation verification (GAO-23-105117).
- Moody’s Analytics. Research on “biotech cluster effects” and long-term economic impacts of state subsidies (2024 Special Report: Biotechnology & Regional Growth).
Aaron Ackerman is a contributor to Direct Line News. He can be contacted at Aaron.Ackerman@mcgopclub.com
Direct Line News is a Maryland-based free-access publication committed to the Republican reform tradition.
About The Author
